Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting (POTASSIUM)

Bayer

Status: Completed

Conditions: Primary Hypertension

Treatments: Drug: Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)

Study type: Observational

Funder types: Industry

Identifiers

NCT01392534

KL1010PL (Other Identifier)

15297

Details and patient eligibility

About

One of the most common adverse effects resulting from the therapy with thiazides, thiazide-like diuretics and loop diuretics is increased potassium secretion. Disregulation of plasma potassium may be a life-threatening condition due to increased risk of arrythmias. Moreover, it has been postulated that decrease in plasma potassium level may negatively affect glucose metabolism resulting in the increased risk of new-onset type 2 diabetes.The main goal of this study is to assess the efficacy and safety of telmisartan/hydrochlorothiazide in a broad population of hypertensive patients, including the effects of the therapy on plasma potassium level and also on selected parameters of glucose and lipid metabolism.

Enrollment: 1,586 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• primary hypertension
• age>18 years

Exclusion criteria

• Cholestatic disorders or severe hepatic/renal failure
• allergy to telmisartan or hydrochlorothiazide
• treatment-resistant hypokalemia or hypercalcemia
• pregnancy and lactation period

Trial design

1,586 participants in 1 patient group

Group 1

Treatment:

Drug: Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)